Captopril-stimulated renography is emerging as a useful diagnostic tool in the evaluation of the hypertensive patient. The primary indication for renography with angiotensin converting enzyme (ACE) inhibition is screening hypertensive patients with clinical clues suggestive of renovascular hypertension. The purpose of the screening test is to assist in clinical decision-making. Therefore, clinical investigators and nuclear medicine physicians are encouraged to analyze their data and present results with respect to the number of patients studied, not number of kidneys studied. The overall goal of this combined technology is to identify patients that have the anatomic lesion of renal artery stenosis who are likely to have renin-dependent hypertension (and possibly renal dysfunction) that may be correctable with intervention such as renovascular surgery or percutaneous renal angioplasty. Investigators are strongly encouraged to report renal artery anatomy (normal, renal artery stenosis > 50%, renal artery stenosis ^ 75%, renal artery stenosis occluded), number of arteries affected, systemic blood pressure, and renal function for all patients. Reporting of follow-up data of these parameters is also encouraged.
ASJC Scopus subject areas
- Internal Medicine